Author

J. E. Agius

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Organism:E. coli· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:variant calling· 1 Organism:virus· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

K. Basile· 2 shared S. C.-A. Chen· 2 shared V. Sintchenko· 2 shared W. Fong· 2 shared A. Arnott· 1 shared B. Suliman· 1 shared C. Finemore· 1 shared C. Lam· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

K. Basile

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

STECode: an automated virulence barcode generator to aid clinical and public health risk assessment of Shiga toxin-producing Escherichia coli

E. M. Sim, W. Fong, C. Suster, J. E. Agius, S. Chandra, B. Suliman, Q. Wang, C. Ngo, C. Finemore, S. C.-A. Chen, K. Basile, V. Sintchenko

STECode automates virulence barcode generation for Shiga toxin-producing E. coli to assess pathogenic potential from sequencing data.

bioRxiv · May 7, 2024 · PreprintMicrobiology

Genomic evolution of SARS-CoV-2 variants of concern under in vitro neutralising selection pressure following two doses of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine

K. Basile, J. E. Agius, W. Fong, K. McPhie, M. Fennel, D. Ko, L. Hueston, C. Lam, A. Arnott, S. C.-A. Chen, S. Maddocks, M. V. N. O Sullivan, D. Dwyer, V. Sintchenko, J. Kok, , CIDMLS COVID-19 Study Group

This study assesses the neutralizing antibody titres against SARS-CoV-2 variants Delta and Beta post-Pfizer-BioNTech vaccination, finding significant reductions compared to wild-type virus.

bioRxiv · Sep 24, 2023 · PreprintMicrobiology